Gemtuzumab (CD33) - Research Grid Biosimilar

Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp.calichensis.Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody Label.The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML) .By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death.

P20138

Humanized / CD33 [Homo sapiens]

Unconjugated

Primary Antibodies, Biosimilars

CHO cells

Cancer

>95%

Batch dependent

PBS buffer pH7.5

None

Blue Ice

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

IgG4-kappa

Homo sapiens

CDP-771, CMA-676 (ADC), WAY-CMA-676, gemtuzumab ozogamicin, hP67.6 (naked), hP67.6-calicheamicin (ADC), CD33, CD33